Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGM:ALT
NasdaqGM:ALTBiotechs

Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag for Pemvidutide in MASH Trial

Altimmune recently received FDA Breakthrough Therapy Designation for its investigational drug pemvidutide after mid‑stage data showed significant MASH resolution, and the company plans a 52‑week late‑stage trial to test multiple doses. This designation could shorten regulatory timelines and enhance pemvidutide’s profile in the competitive MASH treatment landscape, potentially reshaping Altimmune’s long‑term product mix and risk profile. Next, we’ll examine how pemvidutide’s Breakthrough...